AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00759733 — intervention group
Intervention type: PROCEDURE
Intervention: blood draw for serum B-type natriuretic peptide
Description: A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
Study NCT00832520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remeron (mirtazapine)
Description: Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance \< 50% or a bilirubin or transaminases > twice the upper limit of normal will take a 7.5 mg dose.~* Drug Administration: Drug will be administered orally, every day for a period of 8 weeks~* Dose modifications: None
Study NCT01582295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Starting dose 40 mg daily
Study NCT00580372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAD
Description: 3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
Study NCT00580372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose cyclophosphamide
Description: Approximately 5-6 weeks after VAD 2 or 3:~Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1
Study NCT00580372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemopoietic stem cell procurement
Description: Collection target = 10 x 10\^6 cells/kg
Study NCT00580372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDAP
Description: Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
Study NCT00580372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hemopoietic Stem Cell Transplant 1
Description: 4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
Study NCT00580372 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hemopoietic Stem Cell Transplant 2
Description: 4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
Study NCT00580372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance
Description: 3 months after Transplant 2: Intron A 3 X 10\^6 units /m2 M-W-F subcutaneously until relapse
Study NCT02859376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sucrose 24%
Description: Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
Study NCT02859376 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sucrose 24%
Description: Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if \< 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
Study NCT04416347 — intervention group
Intervention type: OTHER
Intervention: SARS-CoV2 Infection
Description: Laboratory confirmed SARS-CoV2
Study NCT03472924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: The application of Kinesio Tape® (kinesiotaping) according to the guidelines provided by the Kinesio Taping Association (Kase, K. 2016). A 5 cm width strip of Kinesio Tape® (Kinesio TEX Products, NKT-050, Japan) will be applied from origin (the head of the fibula) to insertion (the medial cuneiform and first metatarsal) of the peroneus longus in a longitudinal direction. The proximal anchors will be applied without tension, and the Kinesio Tape® placed on approximately 50% stretch before being applied over the peroneus longus and the distal anchor point.
Study NCT03726606 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraocular lens
Description: Bilateral implantation of the same intraocular lens.
Study NCT03726606 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular lens
Description: Bilateral implantation of the same intraocular lens.
Study NCT01112020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHG Catheter Dressing Patch
Description: 2% CHG dressing applied to 7 sites
Study NCT01112020 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biopatch
Description: Biopatch applied to 7 sites
Study NCT01112020 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm CHG
Description: Tegaderm CHG IV Securement Dressing applied to 7 sites
Study NCT03389295 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced Target Delineation and Radiation Doses
Description: The target volumes were delineated according to the treatment protocol defined as follows: the GTV of the primary tumor (GTV-P) included retropharyngeal lymph nodes, considering the common phenomena of integration, and the rest involved lymph nodes that were defined as GTV-N. For the GTV-P, involved retropharyngeal lymph nodes and intracavity lesions were delineated according to the post-IC volume, whereas the remainder of the involved tissues (eg, pterygopalatine fossa) were delineated according to the pre-IC volume of the primary lesion as shown by MRI. Post-IC volumes of involved neck lymph nodes were used for GTV-N delineation.~The prescribed dose was 66 Gy to tumors above the slices of skull base or below the orapharynx with less than 5 mm retropharyngeal lymph nodes, or 70.4 Gy to tumors in other slices.
Study NCT03911973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib, 150-180MG IV
Study NCT03911973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: .75-1.00mg
Study NCT01761045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup 1
Description: Consommé soup with Monosodium L-Glutamate (MSG)
Study NCT01761045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soup 2
Description: Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
Study NCT01761045 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soup 3
Description: Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
Study NCT00878111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: First cohort: iv q3W 60 mcg/sqm over 120 min\*~Second cohort: iv q3W 80 mcg/sqm over 120 min\*~Third cohort: iv q3W 100 mcg/sqm over 120 min\*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min\*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min\*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min\*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min\*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min\*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min\*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min\*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min\*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min\*~\* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period.
Study NCT02293447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine per-embolization
Description: 10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
Study NCT02293447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine post-embolization
Description: 10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
Study NCT04118270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Afib 2gether TM Mobile Application
Description: The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
Study NCT04489251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Protein Elisa analysis, microRNA analysis, whole exome sequencing
Description: ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing.
Study NCT02546765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen & IV propofol
Description: use of IV tylenol and IV propofol for pain and sedation (respectively)
Study NCT02546765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen & IV dexmedetomidine
Description: use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
Study NCT02546765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV propofol & placebo
Description: use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
Study NCT02546765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV dexmedetomidine & placebo
Description: use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
Study NCT01660321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinosad
Description: A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
Study NCT00036751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally
Study NCT00036751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02698748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
Study NCT02698748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
Study NCT02669966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
Study NCT02034630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study NCT01377064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Group
Description: 9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
Study NCT01377064 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Group
Description: No intervention, the group will be followed under their standard medical care.
Study NCT04919291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topoguided LASIK
Description: Topoguided ablation profile on dominant eye
Study NCT04919291 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized LASIK
Description: Wavefront optimized ablation profile on non-dominant eye
Study NCT04095728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brain Octane Oil
Description: Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
Study NCT04095728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
Study NCT02580851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic test - cardiac magnetic resonance imaging
Study NCT02580851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic test - coronary angiography
Study NCT02109562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
Study NCT02109562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
Study NCT02109562 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
Study NCT02109562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
Study NCT04425720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSignals Biosensor 1AX*
Description: Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX\* and a pulse oximeter.
Study NCT04425720 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This group will be treated based on standard of care at our institution.
Study NCT00947700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment, Monitoring & Intervention
Description: Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
Study NCT01248286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain rice
Description: Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
Study NCT01248286 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain rice
Description: Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
Study NCT03688399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far > intermediate > near
Study NCT03688399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation comparator
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far > near > intermediate
Study NCT00288249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Study NCT00288249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Study NCT00288249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Study NCT00288249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Study NCT00488111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate was used 15min before operation
Study NCT00488111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6% Starch
Description: 6% Starch was used 15min before operation
Study NCT03392792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator
Description: role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA
Study NCT03392792 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: role of thrombectomy in patient with acute ischemic stroke
Study NCT02958007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education on Exercise for Recovery
Description: A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
Study NCT02958007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced supervised fitness training
Description: A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
Study NCT02321930 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: tofacitinib 5mg po bid
Study NCT02483377 — intervention group
Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02483377 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT01164566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic procedure
Study NCT01164566 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00971763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00971763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00971763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00971763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone
Study NCT00971763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00664495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Weight Loss
Study NCT00664495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Weight Loss
Study NCT00664495 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Without Weight Loss
Study NCT00199602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarine - low molecular heparin
Study NCT02441413 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Resolution Computed Tomography scans
Description: A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1.
Study NCT04475640 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample
Study NCT04475640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing
Study NCT00470054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO
Study NCT00798135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
Study NCT01129921 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Lumbar Decompression
Description: Fluoroscopic percutaneous lumbar decompression of the central spinal canal
Study NCT01129921 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham lumbar decompression
Description: Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
Study NCT02876120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Implementation
Description: Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.